Report #2827150

Received Feb 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: —
Recovered: Recovered
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RSV	RSV (AREXVY)	GLAXOSMITHKLINE BIOLOGICALS	1	UNK	—

Symptoms (3)

ErythemaFatigueHeadache

Symptom narrative

Erythema; fatigue; headache; This non-serious case was reported by a consumer via sales rep and described the occurrence of erythema in a female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received the 1st dose of Arexvy (unknown arm). On an unknown date, an unknown time after receiving Arexvy, the patient experienced erythema (Verbatim: Erythema), fatigue (Verbatim: fatigue) and headache (Verbatim: headache). The outcome of the erythema, fatigue and headache were resolved. The reporter considered the erythema, fatigue and headache to be related to Arexvy. The company considered the erythema, fatigue and headache to be related to Arexvy. Additional Information: GSK Receipt Date: 14-FEB-2025 The patient received Arexvy and had erythema, fatigue, headache.